Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-Kallikrein 3/KLK3 Antibody (4P120) is a Rabbit antibody targeting Kallikrein 3/KLK3. Anti-Kallikrein 3/KLK3 Antibody (4P120) can be used in WB,ICC/IF,IHC.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 μL | $298 | 7-10 days | |
100 μL | $497 | 7-10 days |
Description | Anti-Kallikrein 3/KLK3 Antibody (4P120) is a Rabbit antibody targeting Kallikrein 3/KLK3. Anti-Kallikrein 3/KLK3 Antibody (4P120) can be used in WB,ICC/IF,IHC. |
Ig Type | IgG |
Reactivity | Human |
Application | |
Recommended Dose | WB: 1:1000; IHC: 1:50-200; ICC/IF: 1:50-200 |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | Recombinant Antibody |
Purification | ProA affinity purified |
Appearance | Liquid |
Formulation | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
Research Background | Prostate specific antigen (PSA), also designated γ-seminoprotein, seminin, p30 antigen, semenogelase, and kallikrein 3 (KLK3), was first identified as a glycoprotein in human seminal plasma. PSA was determined by sequence similarity to be a member of the kallikrein subfamily of trypsin proteases. PSA is a serine protease that hydrolyzes the major human seminal protein, the seminal plasma mobility inhibitor precursor, or semenogelin I (SPMIP or SgI), which leads to semen liquification. PSA production and expression are highest in normal, benign hyperplastic and cancerous tissues of the prostate, although PSA has also been detected in accessory male sex glands and in breast cancer. PSA has been identified as an aid in the early detection of prostate cancer and is a commonly used tumor marker. |
Conjucates | Unconjugated |
Immunogen | Recombinant Protein |
Antigen Species | Recombinant Protein |
Uniprot ID |
Molecular Weight | Theoretical: 34 kDa. |
Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.